ASCEND Trial: Aspirin Prevents Serious Vascular Events in Diabetes

This article originally appeared on

The American Journal of Managed Care.

Serious vascular events in patients with diabetes can be prevented with aspirin use, according to results of the ASCEND (A Study of Cardiovascular Events iN Diabetes) trial, which were presented at the ongoing ESC Congress in Munich, Germany.

The results were simultaneously published in

The New England Journal of Medicine

.

¹

A substantial amount of evidence exists linking diabetes with heart disease, and The Framingham Heart Study was the first to show

that patients with type 2 diabetes are more susceptible to heart disease. Aspirin use has, of course, been found to benefit patients with cardiovascular (CV) disease, and joint guidelines

²

developed by the American Heart Association and the American College of Cardiology Foundation recommend a 75- to 162-mg daily dose of aspirin in all patients with coronary artery disease.

However, the value of this antiinflammatory agent in preventing the first CV event in patients undergoing treatment for diabetes remains unknown.

The ASCEND trial was designed to randomly assign 15,480 adults with diabetes to receive 100 mg of aspirin daily, or a matching placebo. Trial participants did not have any hint of CV disease. Efficacy and safety were monitored and measured as the first serious vascular event (myocardial infarction, stroke, or transient ischemic attack; or death from any vascular cause, excluding any confirmed intracranial hemorrhage) and the first major bleeding event (intracranial hemorrhage, sight-threatening bleeding event in the eye, gastrointestinal bleeding, or other serious bleeding), respectively. Gastrointestinal (GI) tract cancers were monitored as secondary outcomes.

Click to continue reading on The American Journal of Managed Care.